Drug intelligence / Profile preview

Feminax

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral
01

Overview

Feminax is a brand of over-the-counter (OTC) medications specifically formulated for the relief of period pain (primary dysmenorrhea) and associated symptoms such as abdominal cramps, headache, and muscular pain. Originally developed by Bayer and subsequently acquired by Prestige Consumer Healthcare, the brand encompasses several different formulations. The most prominent current products include **Feminax Express**, which contains ibuprofen lysine for rapid absorption, and **Feminax Ultra**, which contains naproxen. These active ingredients belong to the non-steroidal anti-inflammatory drug (NSAID) class and work by inhibiting the cyclooxygenase (COX) enzymes. This inhibition reduces the synthesis of prostaglandins in the uterus, which are the primary mediators of the uterine contractions and inflammatory responses that cause menstrual distress. Historically, the brand also included a combination product containing paracetamol, codeine, caffeine, and hyoscine, though the brand's current identity is centered on NSAID-based relief.

Brand names
FeminaxFeminax ExpressFeminax Ultra
Other names
Ibuprofen lysineNaproxen
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Feminax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Feminax.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call